Bioneer Deal May Point To Yuhan R&D Strategy Change
This article was originally published in PharmAsia News
Yuhan has been seen as one of the less aggressive South Korean pharma firms in terms of beefing up R&D. But now, the company may be shifting its strategy as it has decided to become the second biggest shareholder of local bioventure Bioneer, in a move to strengthen its pipeline including immuno-oncology drugs and to diversify into new businesses.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.